TTK Healthcare Limited: FY 2026 Financial Update

TTK Healthcare reported ₹857.28 crore in revenue for FY 2026 and ₹65.68 crore in profit after tax.

Reader Takeaway: Revenue growth offset by profit decline due to exceptional items; dividend payout offers shareholder returns.

What just happened

TTK Healthcare Limited announced its financial results for the fiscal year ended March 31, 2026. The company achieved a revenue of ₹857.28 crore, marking a 6.96% increase from the previous fiscal year's ₹801.49 crore. However, its Profit After Tax (PAT) saw a decline of 19.57%, falling to ₹65.68 crore from ₹81.66 crore in FY 2025.

Why this matters

The results indicate a mixed performance. While the company managed to grow its top line, the significant drop in net profit, partly attributed to exceptional items, raises questions about cost management and operational efficiency. The recommended dividend offers some return to shareholders amidst the profit dip.

The backstory

In the previous fiscal year (FY 2025), TTK Healthcare had reported a net profit gain of ₹13.91 crore from exceptional items. This year, exceptional items resulted in a net charge of ₹4.07 crore, a swing that directly impacted the year-on-year profit comparison. The company has also noted management's focus on revising wage structures.

What changes now

The Board has proposed a dividend of ₹10 per equity share (100%) for FY 2026, subject to shareholder approval. Furthermore, Mr. T T Raghunathan has been approved for reappointment as Executive Chairman for a five-year term starting November 1, 2026, ensuring leadership continuity.

Risks to watch

Investors will be watching how the company addresses the profitability pressures, particularly the impact of exceptional items and the operational adjustments like wage structure revisions. The ability to translate revenue growth into improved bottom-line performance will be key.

Context metrics (time-bound)

• Revenue FY26: ₹857.28 crore (up 6.96% from ₹801.49 crore in FY25)
• Profit After Tax FY26: ₹65.68 crore (down 19.57% from ₹81.66 crore in FY25)
• Exceptional Items Impact FY26: Net charge of ₹4.07 crore (vs. Net gain of ₹13.91 crore in FY25)

What to track next

Shareholder approval for the dividend and the reappointment of the Executive Chairman will be crucial. Monitoring the company's financial performance in the upcoming quarters, especially concerning profit margins and the management of exceptional items, will be important for investors.

Auditor and Regulatory Update

The Statutory Auditors provided an unmodified audit opinion on the financial results. M/s Geeyes & Co. has been appointed as the Cost Auditor for FY 2026-27.